טוען...
Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
BACKGROUND: The mammalian target of rapamycin (mTOR) inhibitor everolimus is used in the treatment of breast cancer, neuroendocrine tumors, and renal cancer. The approved 10 mg once-daily dose is associated with considerable adverse effects and it has been suggested that these are associated with th...
שמור ב:
| הוצא לאור ב: | Clin Pharmacokinet |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer International Publishing
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5904242/ https://ncbi.nlm.nih.gov/pubmed/28762135 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-017-0582-9 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|